Checkpoint inhibitors, particularly antibodies blocking programmed cell death 1 (anti-PD1) and programmed cell death 1 ligand 1 (anti–PD-L1) proteins, have revolutionized cancer treatment and have gained Food and Drug Administration approval for use in multiple malignancies (1). The gene discussed is PDCD1; the disease is cancer.